Cargando…

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

AIMS: Individuals with diabetes and chronic kidney disease (CKD) are at high risk for renal events. Recent trials of novel treatments have been negative, possibly because of variability in response to treatment of the target risk factor. Atrasentan is a selective endothelin A receptor antagonist tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heerspink, Hiddo J. L., Andress, Dennis L., Bakris, George, Brennan, John J., Correa‐Rotter, Ricardo, Dey, Jyotirmoy, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John, Perkovic, Vlado, Tobe, Sheldon, Wigderson, Melissa, Parving, Hans‐Henrik, de Zeeuw, Dick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Clinical Trial Design
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969254/ https://www.ncbi.nlm.nih.gov/pubmed/29405626 http://dx.doi.org/10.1111/dom.13245

Ejemplares similares

Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Baseline characteristics and enrichment results from the SONAR trial
por: Heerspink, Hiddo J.L., et al.
Publicado: (2018)

Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Koomen, Jeroen V., et al.
Publicado: (2021)

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Webb, David J., et al.
Publicado: (2017)

Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease
por: Smeijer, J. David, et al.
Publicado: (2022)

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
por: Koomen, Jeroen V., et al.
Publicado: (2018)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
por: Smeijer, J. David, et al.
Publicado: (2023)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy
por: Sinkeler, Steef J., et al.
Publicado: (2013)

Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy
por: Kang, Wen-Ling, et al.
Publicado: (2016)

Corrigendum: Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy
por: Kang, Wen-Ling, et al.
Publicado: (2018)

Targeting the Endothelin A Receptor in IgA Nephropathy
por: Kohan, Donald E., et al.
Publicado: (2023)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study
por: Coyne, Daniel W., et al.
Publicado: (2013)

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
por: Barratt, Jonathan, et al.
Publicado: (2023)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Diabetic nephropathy
por: Zelmanovitz, Themis, et al.
Publicado: (2009)

Comparative analysis of diabetic nephropathy and non-diabetic nephropathy disease
por: Chen, Qiuxiang, et al.
Publicado: (2017)

Epigenetics in the pathogenesis of diabetic nephropathy: Epigenetics in the pathogenesis of diabetic nephropathy
por: Li, Xue, et al.
Publicado: (2021)

Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes: An Inception Cohort Study
por: Hovind, Peter, et al.
Publicado: (2009)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Diabetic Nephropathy without Diabetes
por: López-Revuelta, Katia, et al.
Publicado: (2015)

Non-diabetic nephropathy in diabetics
Publicado: (2014)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Inflammation in Diabetic Nephropathy
por: Lim, Andy K. H., et al.
Publicado: (2012)

Silymarin and diabetic nephropathy
por: Rafieian-Kopaie, Mahmoud, et al.
Publicado: (2012)

Ginger and diabetic nephropathy
por: Rafieian-Kopaei, Mahmoud, et al.
Publicado: (2013)

The Genetics of Diabetic Nephropathy
por: Brennan, Eoin, et al.
Publicado: (2013)

Pathogenesis of diabetic nephropathy
por: Cao, Zemin, et al.
Publicado: (2011)

6. Diabetic Nephropathy
por: Kovács, Gábor L.
Publicado: (2009)

Angiopoietins and diabetic nephropathy
por: Gnudi, Luigi
Publicado: (2016)

Roles and crosstalks of macrophages in diabetic nephropathy
por: Li, Hai-Di, et al.
Publicado: (2022)

Novel Susceptibility Locus at 22q11 for Diabetic Nephropathy in Type 1 Diabetes
por: Wessman, Maija, et al.
Publicado: (2011)

Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis
por: Ren, Song, et al.
Publicado: (2017)

Intrarenal Dopamine Inhibits Progression of Diabetic Nephropathy
por: Zhang, Ming-Zhi, et al.
Publicado: (2012)

Blood Pressure and Diabetic Nephropathy
por: Bloomgarden, Zachary T.
Publicado: (2010)

The Role of Visfatin in Diabetic Nephropathy
por: Kang, Young Sun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_e2dafgelb4vvb1q4pvr4rdgvrs